Instil Bio, Inc. (TIL) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 5.39M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -37.17M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $5.39M | $-37.17M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $6.18M | $-55.03M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $8.69M | $-78.58M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $11.59M | $-80.84M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $13.89M | $-89.45M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $16.24M | $-80.15M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $17.26M | $-73.54M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $17.31M | $-74.74M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $20.65M | (m) | $17.91M | $-117.83M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $26.19M | (m) | $18.15M | $-124.68M | $6.55M | (m) | (m) | -19.02× | Reported |
| 2023-12-31 | $39.60M | (m) | $18.17M | $-159.17M | $5.21M | (m) | (m) | -30.56× | Reported |
| 2023-09-30 | $58.34M | (m) | $20.26M | $-202.95M | $3.97M | (m) | (m) | -51.07× | Reported |
| 2023-06-30 | $89.51M | (m) | $23.57M | $-192.88M | $2.78M | (m) | (m) | -69.43× | Reported |
| 2023-03-31 | $122.55M | (m) | $27.48M | $-230.62M | $2.52M | (m) | (m) | -91.55× | Reported |
| 2022-12-31 | $141.06M | (m) | $30.44M | $-226.46M | $1.88M | (m) | (m) | -120.26× | Reported |
| 2022-09-30 | $162.91M | (m) | $32.70M | $-223.41M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $152.31M | (m) | $33.46M | $-209.79M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $132.00M | (m) | $30.88M | $-186.44M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $107.25M | $0.00 | $26.20M | $-155.56M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $19.40M | $138.00K | $1.71M | $-33.64M | (m) | 14057.25% | 1236.23% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |